3 Stocks Seeing Insider Cluster Buys Right Now
When insiders start buying their own stock with real money, it pays to pay attention.
Not because insiders are always right.
They aren’t.
But cluster buying is one of the cleaner signals you’ll ever get from inside the building. The Wall Street Journal recently reported that insider purchases often come after sharp drawdowns and frequently show up in clusters, while research reviewed by 2iQ found that cluster purchases produced larger price impacts and stronger market reactions than non-cluster buys.
That still does not make insider buying a magic trick.
Sometimes insiders are early. Sometimes the bounce fades. The same WSJ analysis found the median stock rose about 2% a month after large insider purchases, but many of those recoveries lost steam after that.
That’s why the best setup is not just insider buying.
It’s insider buying plus a real business story.
That’s what makes the next three names interesting.
The biggest vote of confidence: TriSalus insiders are buying into a commercial rampCompany: TriSalus Life Sciences, Inc. (SYM: TLSI) TriSalus is trading around $4.22, giving it a market cap of about $232 million. This is the kind of stock where insider buying actually means something. According to Insider Screener, TriSalus has seen six insider buy transactions totaling about $1.79 million over the last 90 days, with five insiders stepping in. Two of the clearest receipts came on February 23, when CEO Mary Szela bought 30,487 shares at $4.10, and director William Valle bought the exact same amount at the exact same price. That is not random. That is coordinated conviction. And the operating story gives those buys some weight. In its March 5 earnings release, TriSalus said fourth-quarter revenue came in at $13.2 million, up 60% year over year, while full-year 2025 revenue hit $45.2 million, up 53%. The company also reaffirmed 2026 revenue guidance of $60 million to $62 million and said it had recently raised $46 million in gross proceeds through a public offering. That’s the bull case. A small company. A real commercial ramp. A big insider cluster. And a setup where management is buying while the stock is still priced like the market doesn’t fully trust the story yet. The risk is obvious, too. TriSalus is still losing money, and smaller med-tech names can get thrown around hard if growth slips or capital needs change. The company reported an adjusted EBITDA loss of $0.9 million in the fourth quarter and $17.2 million for the full year. So no, this is not a “safe” stock. It is a signal stock. And the signal is loud. |
The biotech setup: Immuneering insiders are buying ahead of a catalyst calendarCompany: Immuneering Corporation (SYM: IMRX) Immuneering is trading around $5.55, with a market cap of roughly $254 million. This is the pure biotech version of insider accumulation. Insider Screener says Immuneering logged five insider buy transactions totaling $234,342.66 over the last 90 days. The individual filings back that up: director Peter Feinberg bought 20,000 shares at $4.3452 on January 12, director Thomas Schall bought 21,645 shares at $4.6681 on January 15, and Chief Business Officer Harold Brakewood bought 5,250 shares at $4.76 on January 16. That’s the kind of pattern you want to see in biotech. Not one lonely director tossing in a token buy. Multiple insiders stepping up around the same time. And the backdrop is not empty. In its March 6 update, Immuneering said its ongoing Phase 2a trial of atebimetinib plus mGnP in first-line pancreatic cancer patients showed 64% overall survival at 12 months, well above the 35% benchmark it cited for standard-of-care GnP. The company also said it remains on track for an expanded pancreatic cancer data readout in the first half of 2026, expects to dose the first patient in its pivotal Phase 3 MAPKeeper 301 trial in mid-2026, and ended 2025 with $217 million in cash, cash equivalents, and marketable securities — enough runway, it says, into 2029. That is a real catalyst calendar. And catalyst calendars are where biotech stocks can move fast. The catch is simple: biotech can also break your heart in a hurry. A promising setup can get cut in half on one bad readout, one delay, or one shift in the regulatory tone. That is the business. But that’s also why insider buying matters here. These are the people closest to the data, the timeline, and the runway. They’re buying anyway. That’s worth noticing. |
The steadier name: Bausch + Lomb insiders are buying while the operating picture improvesCompany: Bausch + Lomb Corporation (SYM: BLCO) Bausch + Lomb was trading around $17.40 on March 11, with a market cap of about $5.33 billion. This is not the same kind of signal as the first two. It’s messier. Insider Screener says that over the last 90 days, Bausch + Lomb saw about $833,756 of insider purchases, even though insider sales still outweighed buys overall. That matters because it tells you the signal is not “all clear.” It tells you there is still real buying interest from inside the company, but not the kind of unanimous accumulation you’re seeing in TriSalus or Immuneering. Still, the individual buys are real. InsiderTrades shows CEO Brent Saunders bought 32,250 shares at $15.66, a purchase worth about $505,035. And on March 3, director Thomas Ross Sr. bought 4,500 shares at $17.679, according to a Form 4 filing with the SEC. That gets more interesting when you line it up with the operating story. Bausch + Lomb reported $1.405 billion in fourth-quarter 2025 revenue, up 10% from a year earlier. Full-year 2025 revenue reached $5.101 billion, up 6%. Fourth-quarter adjusted EBITDA came in at $326 million, up from $259 million a year earlier. The company also said fourth-quarter MIEBO sales hit $112 million, while its total dry-eye portfolio generated $1.1 billion in 2025 revenue. That’s a very different setup from a tiny biotech or med-tech name. This one has scale. It has real segments. It has real operating leverage. And because Bausch + Lomb is a global eye-health company spanning vision care, pharmaceuticals, and surgical products, the insider buying here looks less like a moonshot bet and more like a confidence vote in execution. That matters if you want a name with insider support but less drama than the smaller companies. Same signal. Different risk. So what’s the takeaway? TriSalus looks like the highest-conviction insider story relative to its size. Immuneering looks like the catalyst trade. Bausch + Lomb looks like the steadier operator with insider support and a real revenue base underneath it. Three names. Three different risk profiles. One common thread: the people closest to the numbers are buying. That doesn’t guarantee upside. But it usually means there’s something worth looking at before the rest of the market catches on. |
Found this helpful? Share it with others.
Written by Ian Cooper